

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Grossman Adam S</u> (Last) (First) (Middle) C/O ADMA BIOLOGICS, INC. 65 COMMERCE WAY (Street) HACKENSACK NJ 07601 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>R&R ACQUISITION VI, INC [NONE]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President & CEO
	3. Date of Earliest Transaction (Month/Day/Year) 02/13/2012	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.0001 per share	02/13/2012		A ⁽¹⁾		438,919	A	(1)	438,919	I	See Footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to purchase	\$3.4	02/13/2012		A ⁽¹⁾		33,088		(3)	02/11/2018	Common Stock	33,088	(1)	33,088	D	
Options to purchase	\$9.6	02/13/2012		A ⁽¹⁾		212,134		(4)	02/13/2022	Common Stock	212,134	(1)	212,134	D	

Explanation of Responses:

- On February 13, 2012, the issuer's wholly-owned subsidiary merged with ADMA Biologics, Inc., a privately-held Delaware corporation ("Former ADMA"). The issuer changed its name to ADMA Biologics, Inc. In connection with the merger and pursuant to the terms of the merger agreement, holders of Former ADMA's common stock received the same number of shares of the issuer's common stock and holders of options to purchase Former ADMA's common stock received options to purchase the same number of shares of the issuer's common stock at the same exercise price. The reporting person, a former security holder of Former ADMA, acquired the issuer's securities in exchange for securities of Former ADMA. The issuer's shares of common stock are not currently listed on an exchange or quoted on the OTC Bulletin Board.
- These shares are held of record by Hariden, LLC, of which the reporting person is the managing member.
- These options were issued in exchange for Former ADMA's options granted on February 11, 2008 and vesting over four years.
- These options were issued in exchange for options granted to the reporting person in connection with the reporting person's employment agreement. The options vested 25% on February 13, 2012, with the remaining 75% vesting in equal monthly installments over the following 48 months of continued employment.

/s/ Adam S. Grossman

02/15/2012

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.